

YR0112

Leader in Biomolecular Solutions for Life Science



Human CD11a Monoclonal Antibody, Endotoxin 0.05 EU/mg

Catalog No.: YR0112

Basic Information

Molecular Weight

150 kDa

Endotoxin

<0.05EU/mg (<0.00005EU/μg)

Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Efalizumab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Human CD11a

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 6.0

Contact



www.abclonal.com

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)